Navigation Links
Hyderabad Firm To Manufacture Tamiflu In India

Switzerland-based Roche Pharmaceuticals has granted a sub-license to Indian firm Hetero Drugs Limited for the production of 'Oseltamivir' or Tamiflu.// This is the only drug known so far to have any effect on the deadly H5N1 virus or the bird flu virus.

Hetero is based at Hyderabad and will be the nerve-center from where the drug will be distributed across South East Asia and Africa. Commenting on the award of the license, Srinivas Reddy, Director, Hetero Drugs said, "For India, we will make 100, 000 capsules by the end of this month and the remaining 900, 0000 by the end of January." Hetero is on target to manufacture 20 million capsules of Tamiflu for export to the African countries. The drug is to cost 75 INR and Hetero has already invested $17 million towards this particular enterprise. "The whole world is for planning. WHO has advised the countries to stock up to 10 per cent of their population," Reddy said.

Bird flu has stuck with a vengeance in South East Asia and has already claimed 72 human lives. Around 150 million birds have been culled in the region to halt its spread. The World Health Organization fears that if the virus mutates into a form easily transmissible from person to person, then there will be a pandemic with millions of casualties.
'"/>




Page: 1

Related medicine news :

1. Hyderabad To Have Asia’s First Catheter Making Uni
2. Biotechnology Initiatives Planned In Hyderabad
3. US Consulate to Start Hyderabad Operations Next Year
4. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
5. Clampdown On Fake Drugs Manufacturers In India – New Bill Enacte
6. Drugs Manufacturers Capitalizing On The Surge In Demand For Bone Health Care
7. Cipla In India Can Manufacture Drug For Bird Flu
8. Nobel Laureate Finds an Alternate Way to Manufacture Anti-Flu Drug
9. German Manufacturers Find a Solution for DVT
10. Singapore Manufacturer to Bring Ethnic Foods to the World
11. Manufacturer of birth control patch runs into rough ‘patches
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for standing designer ... stand solutions representative to the Minneapolis Home and Garden Show which is being held ... is garnering national attention is the Minneapolis Convention Center. , From its broad ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it came time to ... in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand opening presented ... $51 million to purchase and renovate the 185,000 square-foot office complex, which was ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy ... The technology is so cutting edge, in fact, the U.S. Food and Drug ... procedures. However, successful patient outcomes in certain clinical stem cell procedures have shown ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... certification exam and eligibility requirements effective with the April 2017 testing period. NACCM, ... , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ensure ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... analytics to accurately understand each Medicare Advantage member’s risk, identify any gaps-in-coding, ... This new solution helps transform the HCC Risk Adjustment process from a ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 Persistence Market ... global market for intraoperative imaging, excerpts from which ... US$ 513.9 million. According to the report, the ... the grounds of increasing adoption of minimally-invasive surgeries ... diagnostic imaging for neurosurgeries. The world,s leading medical ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Cardiac Prosthetic ... 9.2% over the next decade to reach approximately $8.9 billion by ... forecasts for all the given segments on global as well as ...
(Date:2/23/2017)... 2017 MabVax Therapeutics Holdings, Inc ... company, announces that it has received notice from ... the initiation a Phase I clinical trial with ... MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s novel ... initiate the phase I clinical trial in patients ...
Breaking Medicine Technology: